Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 20/20 | 1.00 |
| ▸ | TYK2 | P29597 | 19/20 | 1.00 |
| ▸ | P2RX3 | P56373 | 1/20 | 1.00 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 11/20 | 0.94 |
| ▸ | JAK1 | P23458 | 12/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18269708 | 1.00 | JAK3 (1.00) | JAK3TYK2P2RX3P2RX2JAK2 | |
| SCHEMBL18269706 | 0.97 | JAK3 (1.00) | JAK3TYK2P2RX3P2RX2JAK2 | |
| SCHEMBL18269713 | 0.90 | JAK3 (1.00) | JAK3TYK2P2RX3P2RX2JAK2 | |
| SCHEMBL23517167 | 0.89 | JAK3 (0.82) | JAK3TYK2P2RX3P2RX2JAK2 | |
| SCHEMBL29565740 | 0.88 | JAK3 (1.00) | JAK3TYK2P2RX3P2RX2JAK2 | |
| SCHEMBL18269705 | 0.88 | JAK3 (1.00) | JAK3TYK2P2RX3P2RX2JAK2 | |
| SCHEMBL30569798 | 0.88 | JAK3 (1.00) | JAK3TYK2P2RX3P2RX2JAK2 | |
| SCHEMBL18269707 | 0.88 | JAK3 (1.00) | JAK3TYK2P2RX3P2RX2JAK2 | |
| SCHEMBL18263249 | 0.88 | JAK3 (1.00) | JAK3TYK2P2RX3P2RX2JAK2 | |
| SCHEMBL21229652 | 0.87 | TYK2 (0.78) | JAK3TYK2P2RX3P2RX2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3303348-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016191524-A1 | NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-12-01 | — | — | WO | disclosed |